British pharmaceutical powerhouse GlaxoSmithKline (GSK) has unveiled plans to inject $30 billion into its U.S. operations over the next five years, as global drugmakers face mounting pressure from President Donald Trump to boost domestic production.
The announcement came on Wednesday, coinciding with the first day of President Trump’s state visit to the United Kingdom—a visit marked by economic diplomacy and tighter trade expectations.
GSK says the multi-billion-dollar investment will significantly ramp up its research, development, and manufacturing capabilities in the United States, where it currently employs around 15,000 people.
“This week’s state visit brings together two countries that have led the world in science and healthcare innovation,” said Emma Walmsley, CEO of GSK, in a statement highlighting the transatlantic collaboration in pharma and biotech.
A key highlight of the new investment package is a $1.2 billion biologics manufacturing facility planned for Pennsylvania. The state-of-the-art site will focus on cutting-edge treatments for respiratory conditions and cancer, while also integrating artificial intelligence into the drug development pipeline.
Beyond Pennsylvania, the company will also boost innovation across its five U.S. manufacturing sites, part of a broader strategy to modernize production lines and respond to shifting geopolitical and trade pressures.
GSK’s U.S. expansion is expected to create hundreds of highly skilled jobs, further anchoring its presence in one of the world’s largest healthcare markets.
The announcement follows President Trump’s aggressive trade posture since his re-election, which has included sweeping tariffs and a push for “Made in America” manufacturing. The administration has consistently pressured pharmaceutical and tech companies to localize operations, citing concerns over the U.S. trade deficit and national security.
During his UK visit, President Trump praised companies that were “bringing jobs home” and hinted at deeper cooperation between the U.S. and UK in the healthcare and biotech sectors.
GSK’s investment marks one of the largest foreign commitments to U.S. pharmaceutical infrastructure in recent years, signaling a strategic alignment with Washington’s push for supply chain resilience and domestic drug security.
About the Author
